Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Mar 1.

Published in final edited form as: Transl Res. 2020 Oct 22;229:100–114. doi: 10.1016/j.trsl.2020.10.005

Figure 5. — Non-tumor bearing nude rats were administered 5 ml of BRO (6 mg/kg bw) + NAC (0.8 g/kg bw) solution (in PBS, pH 8.0) or PBS (control) IP every other day for 2 weeks; gross evaluation (A) and pathological microscopic evaluation of abdominal organs (with H&E staining) (B) for toxicity is shown. Late (advanced) MCP model of IP mucolytic (versus control) therapy at same dose/frequency as in toxicity studies; pre-and post ascites drainage MRIs at week 5 (MRI of non-tumor bearing rat is also shown) (C); gross pictures of mucinous ascites drained and residual abdominal mucinous tumor at sacrifice (week 5) (D); volume of muinous ascites (E), residual mucinous tumor weight (F), gross body weight (G), and ratio of ascites volume to tumor weight (H). Residual mucinous tumor fragments following IP mucolytic (or control) therapy, treated with OXAL (100 μM) for 24h ex vivo, and subjected to IF assay to quantify DNA adducts (I, J). Error bars represent standard deviation (SD) from triplicate experiments (**P< .01, ***P< .001).

Figure 5. — Non-tumor bearing nude rats were administered 5 ml of BRO (6 mg/kg bw) + NAC (0.8 g/kg bw) solution (in PBS, pH 8.0) or PBS (control) IP every other day for 2 weeks; gross evaluation (A) and pathological microscopic evaluation of abdominal organs (with H&E staining) (B) for toxicity is shown. Late (advanced) MCP model of IP mucolytic (versus control) therapy at same dose/frequency as in toxicity studies; pre-and post ascites drainage MRIs at week 5 (MRI of non-tumor bearing rat is also shown) (C); gross pictures of mucinous ascites drained and residual abdominal mucinous tumor at sacrifice (week 5) (D); volume of muinous ascites (E), residual mucinous tumor weight (F), gross body weight (G), and ratio of ascites volume to tumor weight (H). Residual mucinous tumor fragments following IP mucolytic (or control) therapy, treated with OXAL (100 μM) for 24h ex vivo, and subjected to IF assay to quantify DNA adducts (I, J). Error bars represent standard deviation (SD) from triplicate experiments (**P< .01, ***P< .001).